Sign in Subscribe
Cancer

Microneedle-Based Delivery Systems Show Promise in Targeted Cancer Therapy

Strategic Insights

— 2 min read

Researchers from JSS College of Pharmacy have made significant strides in the development of microneedle-based delivery systems for targeted cancer therapy. These minimally invasive systems have the potential to overcome the limitations of conventional drug delivery methods, enabling direct delivery of chemotherapeutic agents to tumor sites and reducing systemic toxicity. The review, published in Critical Reviews In Therapeutic Drug Carrier Systems, comprehensively examines the applications of microneedles in cancer treatment, including chemotherapy and immunotherapy, as well as their potential in gene therapy.

Key Takeaways:

  • Microneedle-based delivery systems have emerged as a groundbreaking technology in targeted cancer therapy, facilitating the transdermal administration of therapeutic agents.
  • These systems offer a minimally invasive method to overcome the limitations posed by conventional drug delivery systems, enabling direct delivery of chemotherapeutic agents to tumor sites.
  • Microneedles can be used in chemotherapy to maximize drug efficacy and minimize adverse effects, as well as in immunotherapy to deliver immune-modulating agents that activate localized immune responses against cancer cells.
  • The review emphasizes the need for further research and clinical trials to validate the efficacy and safety of microneedles in cancer therapy.
  • The potential of microneedles in gene therapy is addressed, highlighting their ability to deliver genetic material directly to tumor cells, offering a novel approach to cancer treatment.
  • The challenges associated with MN-based therapies, such as ensuring consistent and controlled drug delivery, addressing patient variability, and overcoming manufacturing and scalability issues, are also discussed.
  • The review concludes that the advancements in microneedle technology and the promising results from preclinical and clinical studies underscore their transformative potential in cancer therapy.
  • The researchers emphasize the need for further research and clinical trials to validate the efficacy and safety of microneedles in cancer therapy.

Statistics:

  • 42(5):101-120 is the issue number and page range of the review published in Critical Reviews In Therapeutic Drug Carrier Systems.
  • 2025 is the year in which the research was conducted.
  • 50 North St is the address of Begell House Inc, the publisher of Critical Reviews In Therapeutic Drug Carrier Systems.
  • JSS College of Pharmacy is the institution that conducted the research, located in Mysuru 570015, India.
  • The research involved a team of authors, including K. S. Nagashree, S. M. Simi, R. Pruthvi, Bhavya Malgur Vishweshwaraiah, and Riyaz Ali M. Osmani.

Sources:

  • NewsRx. Findings on Cancer Gene Therapy Detailed by Investigators at JSS College of Pharmacy (Microneedle-mediated Delivery for Targeted Cancer Therapy: a Comprehensive Review). Cancer Weekly. August 5, 2025; p 25.
  • Critical Reviews In Therapeutic Drug Carrier Systems. Microneedle-mediated Delivery for Targeted Cancer Therapy: a Comprehensive Review. 2025;42(5):101-120.
  • Begell House Inc. Critical Reviews In Therapeutic Drug Carrier Systems. 50 North St, Danbury, CT 06810, USA.

Read more